JPH0481967B2 - - Google Patents
Info
- Publication number
- JPH0481967B2 JPH0481967B2 JP25276184A JP25276184A JPH0481967B2 JP H0481967 B2 JPH0481967 B2 JP H0481967B2 JP 25276184 A JP25276184 A JP 25276184A JP 25276184 A JP25276184 A JP 25276184A JP H0481967 B2 JPH0481967 B2 JP H0481967B2
- Authority
- JP
- Japan
- Prior art keywords
- acetyl
- chitohexaose
- infective
- active ingredient
- hexa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004480 active ingredient Substances 0.000 claims description 13
- 229960005475 antiinfective agent Drugs 0.000 claims description 12
- 239000004599 antimicrobial Substances 0.000 claims description 12
- FUHDMRPNDKDRFE-LPUYKFNUSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(2r,3s,4r,5r)-5-acetamido-1,2,4-trihydroxy-6-oxohexan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy- Chemical compound O[C@@H]1[C@@H](NC(C)=O)[C@H](O[C@@H]([C@H](O)[C@H](C=O)NC(=O)C)[C@H](O)CO)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)NC(C)=O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FUHDMRPNDKDRFE-LPUYKFNUSA-N 0.000 claims description 10
- DPTYILOGADPXRZ-RXDSZOQSSA-N Penta-N-acetylchitopentaose Chemical compound O[C@@H]1[C@@H](NC(C)=O)[C@H](O[C@@H]([C@H](O)[C@H](C=O)NC(=O)C)[C@H](O)CO)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 DPTYILOGADPXRZ-RXDSZOQSSA-N 0.000 claims description 8
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 230000002924 anti-infective effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 229920002101 Chitin Polymers 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 206010027906 Monocytosis Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25276184A JPS61130230A (ja) | 1984-11-29 | 1984-11-29 | 抗感染症剤 |
| CA000496106A CA1261264A (en) | 1984-11-29 | 1985-11-25 | Immunopotentiating agents and method |
| EP85308687A EP0183556B1 (en) | 1984-11-29 | 1985-11-28 | Use of chitin- or chitosan-oligomers for the manufacture of a immunopotentiating agent for enhancing the immune response against bacterial and fungal infections and against the growth of tumours |
| DE8585308687T DE3583217D1 (de) | 1984-11-29 | 1985-11-28 | Verwendung von chitin- oder chitosan-oligomeren zur herstellung eines arzneimittels zur staerkung der abwehrkraefte gegen bakterien- und pilzinfektionen und gegen tumorwachstum. |
| DK550685A DK165731C (da) | 1984-11-29 | 1985-11-28 | Anvendelse af chitin eller chitosanoligomerer til fremstilling af immunopotenserende midler |
| US07/363,307 US4971956A (en) | 1984-11-29 | 1989-06-07 | Immunopotentiating agents and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25276184A JPS61130230A (ja) | 1984-11-29 | 1984-11-29 | 抗感染症剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61130230A JPS61130230A (ja) | 1986-06-18 |
| JPH0481967B2 true JPH0481967B2 (ko) | 1992-12-25 |
Family
ID=17241922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25276184A Granted JPS61130230A (ja) | 1984-11-29 | 1984-11-29 | 抗感染症剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61130230A (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001031575A (ja) * | 1999-07-16 | 2001-02-06 | Fujibio Co Ltd | キチン・キトサンによる５−フルオロウラシルの副作用防止方法及びそのための配合剤 |
| JP2001031577A (ja) * | 1999-07-16 | 2001-02-06 | Fujibio Co Ltd | キチン・キトサンによるシスプラチンの副作用防止方法及びそのための配合剤 |
-
1984
- 1984-11-29 JP JP25276184A patent/JPS61130230A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61130230A (ja) | 1986-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103732232B (zh) | 包含抗生素和分散剂或者抗粘结剂的组合物 | |
| Youssef et al. | Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocytogenes infection in athymic nude mice | |
| US20140134140A1 (en) | Mesenchymal stem cell compositions for the treatment of microbial infections | |
| CN101637447B (zh) | 一种西他沙星注射剂及其制备方法 | |
| CN113995744B (zh) | 一种组合物及其抗菌应用 | |
| CN109077945A (zh) | 用于化妆品的溶菌酶组合抑菌剂 | |
| Hoddinott et al. | Determination of bone and fat concentrations following systemic cefamandole and regional cefuroxime administration in patients undergoing knee arthroplasty | |
| KR20060095599A (ko) | 감염 방어능력 및 패혈증 치료능력을 지닌 인삼추출 다당체 | |
| JP2020531568A5 (ko) | ||
| CN101003539A (zh) | 西林类化合物的氨丁三醇盐及其制备方法 | |
| JPH0481967B2 (ko) | ||
| US11998615B2 (en) | Functionalized nanoparticles and their use in treating bacterial infections | |
| US20060073156A1 (en) | Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract | |
| CN110711192A (zh) | 色氨酸增强对革兰氏阴性菌杀菌作用的应用 | |
| WO2009144711A1 (en) | Compositions comprising red microalgae polysaccharides and metals | |
| RU2613708C2 (ru) | Способ лечения угревой болезни | |
| GB2240922A (en) | Bacterial lysate for the treatment of dermatitis | |
| CN107236022A (zh) | 细胞穿透肽的亲脂性化合物偶联物及其在抗菌中的应用 | |
| JPH07503949A (ja) | クラブラン酸塩およびエリスロマイシン誘導体よりなる医薬製剤 | |
| Bennett | Review of selected aspects of pharmacology | |
| JPS61268626A (ja) | 抗感染症剤 | |
| CN108186618A (zh) | 柠檬醛及其衍生物在制备mrsa感染性疾病药物中的新用途 | |
| RU2792679C1 (ru) | Бактерицидная фармацевтическая композиция для парентерального применения в форме лиофилизата с эндолизином | |
| CN108186617A (zh) | 香叶醇及其衍生物在制备mrsa感染性疾病药物中的新用途 | |
| WO2012158002A1 (ru) | Лекарственный препарат «renessans», обладающий антибактериальным, противоязвенным и иммуномодулирующим действием |